



Breakthrough Strategy for new drugs in Cancer Treatment and Neurodegenerative diseases

ViDAC Pharma sees as a determining data the fact that mislocation of active factors in the Cell organization (1) is often the cause of the most dangerous diseases, such as Cancer and Neurodegenerative diseases. Cells are before all organization entities, where each element must be active at its site and at the right time. When a mutation or upregulation occurs impairing this “right function at the right place at the right time”, like in any organization, it can only harm its overall functioning.

ViDAC Pharma is today a pre-IPO public clinical stage biopharmaceutical company which develops first-in-class anti-cancer drugs by modifying the hyper glycolytic (Warburg Effect) Tumor Microenvironment and demonstrated the reality of the above concept by Toposteric* small molecules to reverse the mislocation, while keeping the active site intact. Vidac proved clinically (Phase 2B) this new paradigm in the Non Melanoma Skin cancer Spectrum and extending its reach to treatment of Solid Tumors such as Lung and Breast Cancer as well as exploring Neurodegenerative diseases.

Vidac Pharma drugs displace harmful wrongly anchored factors but do not impair their function thus returning cells to normal metabolism. This is particularly the case in the Warburg effect: High Glycolysis caused by wrong anchoring of upregulated HK2 enzyme blocking the VDAC1 channel induces high proliferation, does not allow for apoptosis to take place and create a lactate rich Tumor Microenvironment unfavorable to immune action.

ViDAC’s innovations target cancer cells overexpressed Hexokinase 2 metabolic checkpoint (HK2) to selectively provoke the programmed death of cancer cells without affecting surrounding normal tissue. ViDAC’s drugs intervene in the cancer cells’ nutrition, triggering dormant self-death mechanism (i.e., the apoptosis) and blocking fast proliferation, returning cells to normal metabolism thus reducing immune depression in tumor’s environment while stimulating anti-tumor immune response in cancer cells only.

Lead first drug: topical *tuvatexib* (VDA-1102) presents highest safety and selective efficacy in patients suffering from Squamous Cell Carcinoma Spectrum: AK/topical SCC as demonstrated in an FDA Phase 2b clinical trial (2019) and in on-going exploratory Phase 2 in Cutaneous T Cell Lymphoma (CTCL) and BCC.

We are at advanced pre-clinical stage and developing new patented very potent molecules family, with the same Mechanism of Action (MOA) for addressing solid tumors either as single treatment or in combination with immunotherapy and cell therapy which effect is impaired by hyper glycolysis of the Tumor microenvironment.

*Toposteric effect is a term that we created to describe modifications of tertiary structure of active factor by small molecules blocking them to bind to a wrong anchor.



Market

Global Market for cSCC is estimated at US\$ 10.3B in 2020 with a CAGR of 7.2% (2). BCC Global Market is estimated at US\$ 6.7B in 2021 with CAGR of 7.9%. In Europe the preferred treatments are topicals (up to 90%) in early grades while in the USA cryosurgery is preferred to the same extent. NMSC is the most frequent diagnosed cancers overall.

In all existing treatment whether surgical and nonsurgical the side effects are the principal factor governing non Compliance and market development on top of the lack of efficacy of some of the treatments.

CTCL represents an unmet medical need of \$900M worldwide equally divided between USA, Europe and Asia Pacific area. It is classified by FDA as Rare disease commending a fast-track regulatory pathway. Global trends such as aging population, global warming and sun exposure in developed and emerging countries contributes to further growth of ViDAC Pharma's total available market in the coming years.

The Solid Tumor market for the two contemplated indications NSCLC is US\$ 22.3B in 2020 and projected to reach US\$40.3B in 2027 (3) & triple Negative BC is estimated at US\$ 900 M in 2021 and expected to reach US\$ 1.3B in 2029 (4).

Both are hyper glycolytic cancers rich in HK2 binding to Mitochondria

Lead Products: VDA-1102 for Non-Melanoma Skin Cancer and CTCL

ViDAC's pipeline includes several first-in-class potential drug candidates for a variety of indications.

VDA-1102 is a very potent, highly selective anti-cancer drug applied topically on skin to treat cSCC SPECTRUM (AK TO topical SCC) recurring disease with incidence rate increasing with age as a primary indication. VDA-1102's mechanism of action, high efficacy and specificity towards cancer cells, position it as a high potential and safe anti-cancer product for large range of NMSC such as CTCL, topical Squamous Cell Carcinoma (SCC) and Basal Cell Carcinoma (BCC). Unlike existing drugs generating severe side effects and pain, VDA-1102 is a first-in-class drug that treats NMSC with minimum effect on the surrounding healthy skin. Because of its unique characteristics and benefits, VDA-1102 is expected to become the drug of choice for first-line non-surgical treatment in a wide range of NMSC indications.

Recent interim data on exploratory Phase 2 showed the potential of the drug for the treatment of CTCL, an unrelated Lymphoma disease confirming the high potential of our new Mode of Action (MOA) on this extremely painful disease which lacks adequate medical treatment and for a variety of others non-Carcinoma types of Cancer. Because of its classification, CTCL exploratory Phase 2 will be followed by proper formulation and will comprise 20-30 patients looking for dose and protocol finding and about the same number of a qualified EMEA/FDA Phase 2B and it is expected that phase 3 will demand as few as 100-150 patients. Exploratory CTCL Phase 2a is on-going in Israel and a Phase 2B planed in USA and Europe under the supervision of KOLs on this disease.



Business Opportunity

The Management by seasoned entrepreneur industrials and a team of highly experienced executive managers conduct further developments. The business opportunity resides in joining a top recognized team of experts who bought-out their company to develop promising anti-cancer treatment based on previously accomplished research and development (\$19M invested in previous cycle including \$5M from Innovation Authorities in Israel). The Company is now Registered in the Hamburg Stock Exchange Q1- 2023 and the Stuttgart Stock Exchange and applying to enter the Main Frankfurt Regulated Exchange.

Financing Plan

Funding from financing activities, both Public and Private will be used to achieve a 20-30 patients Phase 2 in CTCL (Q2 2022), initiate a pre-Phase 3 "real world" Phase 2 for SCC Spectrum (Q3-Q4 2023) as well as BCC and pursue pre-clinical and first in Man and Phase 2 on solid tumors with the new class of molecules.

Further investment will occur by PIPE and Public Offering at market value to prepare a Phase 3 for SCC Spectrum and BCC and conduct a Phase 3 for CTCL as well as to explore back-up compounds & pathologies (Q1'24). Co-development deal for a Phase 3 in SCC Spectrum is also planned as source of financing.

A dual European and/or USA listing and/or M&A is in the program prior to commercialization of the products.

Investors joining ViDAC Pharma's financing plan benefit from the outcomes of \$14M of research and development already invested by entrepreneurs and VCs before management buyout plus \$5M of non-dilutive grants.

Timeline depends on securing Financing.

As a matter of Financial Strategy, the Company will be using subcontractors for many of its activities avoiding Capital Expenses for creating multi-purpose laboratories and personnel. Managing subcontractors is an art that was acquired by many years of experience of the management team.

Leading Team

Max Herzberg, PhD, Active Chairman & CEO

40 years of biotechnology industry experience, one of the founders of the Israel Biotech Industry, founder and board member of several successful biopharmaceutical companies. Inventor of the first API of Vidac.

Yochai Richter, Board Member

Successful entrepreneur. Chairman of Orbotech from its creation up to its \$4B exit.

Christian Policard PhD, Board Member

Former Executive VP of Sanofi and VP of Institut Pasteur, Head of Biotech Life Sciences Consulting firm, Board Member in Biotech and Pharma Companies.

Joseph Tenne CPA : Former CFO of Multinational Companies and Board member as Financial expert in international groups.

Oren Becker PhD, Board Member

Former CEO of ViDAC Pharma, 20 years of experience in the biopharmaceutical industry and chain entrepreneur.

Contact Information:

Max Herzberg PhD, direct +972544257381 or maxherzberg@vidacpharma.com


Yuval Sagiv PhD: CTO, 30 years of experience in running R&D and Drug development processes from concept to Registration with emphasis on Immunological aspects of Cancer.

Sandra Gamzon MBA, COO: 20 Years of experience in running operations in Biotech ventures including commercialization specializing in HR, subcontractors' motivation and team building.

Shuki Cohen CPA: CFO 30 years of experience in working with start-ups and established Companies in the Healthcare territory including budgeting and reporting to Grantors and Institutions and relations with VCs and Banks.

Prof. David Varon MD, CMO, Former Head of Hematology Department Hadassah Hospital-Jerusalem with a vast experience in practicing and researching General Medicine and performing Clinical Trials.

Intellectual Property: Strong patent position with several worldwide composition-of-matter and use patents (to be provided upon request). The Company comprehensive Portfolio covers both New Chemical Entities and the field of targeting HK2 in hyper glycolytic state of the Cancer cells (effect Warburg) as well as its immunological consequences particularly for Immunological and Cell directed treatments.



1: M.C Hung & W. Link: Protein localization in disease and therapy, 2011 Journal of Cell Science 124. 3381-3392

2: <https://www.coherentmarketinsights.com/market-insight/cutaneous-squamous-cell-carcinoma-treatment-market-4280>

3: <https://www.researchandmarkets.com/reports/5303629/non-small-cell-lung-cancer-nsc-therapeutics>

4: <https://www.databridgemarketresearch.com/reports/global-triple-negative-breast-cancer->